Cellumed
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Cellumed makes products used in bone and joint repair, including bone graft materials, total knee replacement implants, and a joint-fluid substitute that eases knee pain.
Its customers are primarily hospitals and surgical teams that use these materials in orthopaedic procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three areas, medical devices, biologics (protein-based therapeutics), and cosmeceuticals, while also pursuing enzyme production for messenger-RNA vaccines through a contract-development arrangement with a German partner.
Summary is AI-generated and may contain errors · figures from DART filings
Cellumed consolidates several subsidiaries under its group, including a biologics unit and environmental and real-estate construction companies, making it a diversified holding structure rather than a pure medical-device business.
Cellumed in five facts
What does Cellumed do?
Cellumed makes products used in bone and joint repair, including bone graft materials, total knee replacement implants, and a joint-fluid substitute that eases knee pain.
Where is Cellumed listed and in which sector?
Cellumed (Korean name: 셀루메드) trades under KRX code 049180 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Cellumed?
Its market capitalisation was US$63.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Cellumed's latest annual revenue and operating profit?
For fiscal year 2025, Cellumed reported revenue of US$105.8M, an operating loss of US$3.9M and a net loss of US$1.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 8.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 13
- [Amended] Shareholder register closure / record date setOct 13
- [Amended] Half-year report (2026.06)Oct 13
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 23
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 13
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 12
- Securities issuance results (voluntary) (third-party placement)Capital raise · Jan 20
- Change of largest shareholderOwnership change · Jan 20
- [Amended] Material event report (rights offering)Capital raise · Jan 12